APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

October 29, 2020
Appili Therapeutics Appoints Drug Development Executive Don Cilla to the Newly Created Position of Chief Development Officer
October 27, 2020
Appili Therapeutics to Present at TSX Life Sciences Investor Day
October 27, 2020
Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program
October 20, 2020
First Participants Dosed in Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes